Nkarta Inc (NKTX)

$2.63 +0.04 (1.54%)
Market Cap 178.29M
Revenue (ttm) 0.00
Net Income (ttm) -108.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 513,689
Avg Vol 778,170
Day's Range N/A - N/A
Shares Out 71.03M
Stochastic %K 87%
Beta 0.54
Analysts Strong Sell
Price Target $11.80

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for...

Industry: Biotechnology
Sector: Healthcare
Phone: 925 407 1049
Address:
1150 Veterans Boulevard, South San Francisco, United States
nightstocker15
nightstocker15 Feb. 26 at 7:22 PM
$NKTX this has a lot more fight up here than the last few times! Flirting with 1 year high, if breaks over can continue to run
0 · Reply
Lukey63
Lukey63 Feb. 25 at 4:45 PM
$NKTX need to break and hold above $2.75. Interesting if you look at the last six months the big up days have been high volume while the steady declines have been smaller. I hope this isn’t another head-fake like Oct.
1 · Reply
purplesniper
purplesniper Feb. 25 at 3:09 PM
$NKTX I need 3 in the next coming weeks
0 · Reply
notatrol
notatrol Feb. 24 at 8:08 PM
$NKTX volume coming in
0 · Reply
nightstocker15
nightstocker15 Feb. 24 at 7:41 PM
$NKTX 😎
0 · Reply
purplesniper
purplesniper Feb. 24 at 7:13 PM
$NKTX YES
1 · Reply
PandaSwingz
PandaSwingz Feb. 23 at 1:30 PM
$NGD $NKTX $CNDT $FN ”’”
0 · Reply
jerzypawlik
jerzypawlik Feb. 21 at 11:01 PM
$NKTX We'll go over 2.5 this week.
0 · Reply
JamesKnee385
JamesKnee385 Feb. 21 at 7:14 AM
$NKTX Nkarta develops NK cell therapies for cancer. Clinical milestones drive valuation swings. Early-stage biotech risk remains high.
1 · Reply
Moni_48
Moni_48 Feb. 19 at 5:23 PM
$NKTX why is this going up today?
1 · Reply
Latest News on NKTX
Nkarta to Participate in Evercore Healthcare Conference

Dec 2, 2025, 7:09 AM EST - 3 months ago

Nkarta to Participate in Evercore Healthcare Conference

Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason

Nov 22, 2025, 8:28 AM EST - 3 months ago

Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nov 10, 2025, 4:01 PM EST - 3 months ago

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nkarta to Participate in November Investor Conferences

Oct 30, 2025, 1:14 PM EDT - 4 months ago

Nkarta to Participate in November Investor Conferences

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Oct 22, 2025, 10:07 AM EDT - 4 months ago

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Nkarta to Participate in a September Investor Conference

Sep 2, 2025, 8:01 AM EDT - 6 months ago

Nkarta to Participate in a September Investor Conference

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 12, 2025, 4:01 PM EDT - 7 months ago

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Jul 23, 2025, 8:01 AM EDT - 7 months ago

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

Jul 22, 2025, 12:40 AM EDT - 7 months ago

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Jun 6, 2025, 8:52 AM EDT - 9 months ago

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 15, 2025, 3:46 PM EDT - 10 months ago

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 14, 2025, 4:01 PM EDT - 10 months ago

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Nkarta to Participate in an April Investor Conference

Apr 1, 2025, 8:01 AM EDT - 11 months ago

Nkarta to Participate in an April Investor Conference

Nkarta: Grinding Lower, Trying To Find Support

Mar 31, 2025, 10:41 AM EDT - 11 months ago

Nkarta: Grinding Lower, Trying To Find Support

Nkarta: Betting On The Turnaround

Mar 31, 2025, 10:15 AM EDT - 11 months ago

Nkarta: Betting On The Turnaround

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Mar 27, 2025, 12:50 PM EDT - 1 year ago

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Nkarta to Participate in March Investor Conferences

Feb 25, 2025, 8:01 AM EST - 1 year ago

Nkarta to Participate in March Investor Conferences

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Dec 5, 2024, 6:01 AM EST - 1 year ago

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nkarta to Participate in an Upcoming Investor Conference

Nov 26, 2024, 7:02 AM EST - 1 year ago

Nkarta to Participate in an Upcoming Investor Conference

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nov 7, 2024, 4:02 PM EST - 1 year ago

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nkarta to Participate in Upcoming Investor Conference

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conference

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Aug 14, 2024, 3:08 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 9:03 PM EDT - 1 year ago

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Jul 24, 2024, 6:00 AM EDT - 1 year ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Jul 16, 2024, 6:01 AM EDT - 1 year ago

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Jun 27, 2024, 6:00 AM EDT - 1 year ago

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Jun 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Nkarta: Finally An Attractive Valuation

May 25, 2024, 2:20 AM EDT - 1 year ago

Nkarta: Finally An Attractive Valuation

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

May 9, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 27, 2024, 10:27 AM EDT - 1 year ago

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 8, 2024, 12:55 PM EDT - 2 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 5, 2024, 3:35 PM EDT - 2 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Nkarta to Participate in Upcoming Investor Conferences

Apr 3, 2024, 4:02 PM EDT - 2 years ago

Nkarta to Participate in Upcoming Investor Conferences

Nkarta: NK Cell Therapy Advancement On Two Fronts

Mar 25, 2024, 4:03 PM EDT - 2 years ago

Nkarta: NK Cell Therapy Advancement On Two Fronts

Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 25, 2024, 6:30 AM EDT - 2 years ago

Nkarta Announces Pricing of $240 Million Underwritten Offering

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Mar 21, 2024, 4:01 PM EDT - 2 years ago

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Mar 13, 2024, 1:22 PM EDT - 2 years ago

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Nkarta: Possible Upside From H1 Update, If Positive

Jan 25, 2024, 12:12 PM EST - 2 years ago

Nkarta: Possible Upside From H1 Update, If Positive

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Dec 9, 2023, 8:31 PM EST - 2 years ago

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 9, 2023, 4:02 PM EST - 2 years ago

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nkarta to Participate at Upcoming Investor Conferences

Nov 7, 2023, 8:02 AM EST - 2 years ago

Nkarta to Participate at Upcoming Investor Conferences

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Oct 17, 2023, 11:47 AM EDT - 2 years ago

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Oct 17, 2023, 7:01 AM EDT - 2 years ago

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Oct 16, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 10, 2023, 7:01 AM EDT - 2 years ago

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Nkarta to Participate at Upcoming Investor Conference

Aug 3, 2023, 8:02 AM EDT - 2 years ago

Nkarta to Participate at Upcoming Investor Conference

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

Jul 5, 2023, 4:02 PM EDT - 2 years ago

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

nightstocker15
nightstocker15 Feb. 26 at 7:22 PM
$NKTX this has a lot more fight up here than the last few times! Flirting with 1 year high, if breaks over can continue to run
0 · Reply
Lukey63
Lukey63 Feb. 25 at 4:45 PM
$NKTX need to break and hold above $2.75. Interesting if you look at the last six months the big up days have been high volume while the steady declines have been smaller. I hope this isn’t another head-fake like Oct.
1 · Reply
purplesniper
purplesniper Feb. 25 at 3:09 PM
$NKTX I need 3 in the next coming weeks
0 · Reply
notatrol
notatrol Feb. 24 at 8:08 PM
$NKTX volume coming in
0 · Reply
nightstocker15
nightstocker15 Feb. 24 at 7:41 PM
$NKTX 😎
0 · Reply
purplesniper
purplesniper Feb. 24 at 7:13 PM
$NKTX YES
1 · Reply
PandaSwingz
PandaSwingz Feb. 23 at 1:30 PM
$NGD $NKTX $CNDT $FN ”’”
0 · Reply
jerzypawlik
jerzypawlik Feb. 21 at 11:01 PM
$NKTX We'll go over 2.5 this week.
0 · Reply
JamesKnee385
JamesKnee385 Feb. 21 at 7:14 AM
$NKTX Nkarta develops NK cell therapies for cancer. Clinical milestones drive valuation swings. Early-stage biotech risk remains high.
1 · Reply
Moni_48
Moni_48 Feb. 19 at 5:23 PM
$NKTX why is this going up today?
1 · Reply
purplesniper
purplesniper Feb. 19 at 4:28 PM
$NKTX
0 · Reply
canuck_trader92
canuck_trader92 Feb. 18 at 8:24 PM
$NKTX Any chance this breaksthrough $2.60 - $2.70?
1 · Reply
pelyod
pelyod Feb. 18 at 6:01 PM
$NKTX We're at the H&S shoulder line, and showing pops of volume. MACD curling positive, and a Golden Cross on the daily. RSI is only 56- IMO, we could really run here.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 1:13 PM
$NKTX RSI: 25.51, MACD: -0.0225 Vol: 0.21, MA20: 2.18, MA50: 2.01 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
FarhodKh
FarhodKh Feb. 14 at 5:57 PM
$NKTX Coming soon... This is not financial advice!!!
0 · Reply
BioTechHealthX
BioTechHealthX Feb. 14 at 4:34 AM
$NKTX Nkarta (NASDAQ: NKTX) isn’t chasing crowded oncology anymore—it’s aiming at B cell–driven autoimmune disease with an off-the-shelf CAR-NK therapy. Here’s why the pivot matters, what “immune reset” could mean for patients, and why 2026 data could flip the NKTX narrative fast. https://biotechhealthx.com/biotech-news/nkarta-nktxs-plot-twist-from-cancer-chaos-to-autoimmune-immune-reset-hype/
0 · Reply
None_
None_ Feb. 11 at 10:51 PM
$NKTX $ALLO $CRBU $FATE https://www.fiercebiotech.com/biotech/only-thing-saves-us-data-allogeneic-car-t-biotechs-fight-relevance-industry-moves
1 · Reply
DipCityGhost
DipCityGhost Feb. 10 at 12:00 PM
$NKTX is a biotech developing NK cell engagers for cancer; the technology is promising but unproven, with high clinical and regulatory risk.
2 · Reply
Lukey63
Lukey63 Feb. 9 at 4:37 PM
$NKTX I grow increasingly impatient with this POS stock.
1 · Reply
canuck_trader92
canuck_trader92 Feb. 5 at 5:43 PM
$NKTX no hope for this one!
0 · Reply
youbi336
youbi336 Feb. 4 at 5:37 PM
$NKTX Dropped on really low volume too. This doesn't seem like institution/insider selling. Probably just grabbing liquidity that was left between 2.04 - 2.10. If it breaks 1.92, then we're in trouble
0 · Reply
youbi336
youbi336 Feb. 4 at 4:17 PM
$NKTX Couldn't hold the 200 EMA. Needs a catalyst. It won't go up otherwise.
0 · Reply